全球视锥细胞营养不良症市场：按类型、治疗类型、最终用户、地区、规模、趋势、COVID-19 的影响进行分析，预测到 2030 年

视锥细胞-视桿细胞营养不良症是用来描述一组影响视网膜视锥细胞的遗传性眼科疾病的术语。这些细胞排列在眼球后部称为视网膜的区域。视锥细胞遍布视网膜，但集中在中心（黄斑部）。这些有助于中央视觉（阅读）。视桿光感受器遍布视网膜除中心以外的区域，负责夜视。 2024 年全球视锥细胞-视桿细胞营养不良症市场规模价值为 1.3129 亿美元，预计到 2030 年将达到 1.7759 亿美元。

全球视锥细胞-视桿细胞营养不良症市场的成长受到人们对遗传疾病认知的不断提高和对有效治疗的需求不断增加等因素的推动。糖尿病对视锥细胞营养不良症市场的成长也有重大影响。美国国家眼科研究所最近的估计表明，仅在美国，每 40,000 人中就有大约 1 人患有视锥细胞营养不良症，这凸显了对有效治疗方案的迫切需求。目前尚无治疗方法可以阻止视锥桿细胞营养不良症 (CRD) 患者的视力丧失。 CRD 治疗的主要目标是减缓疾病的进展、保留剩余的视力并改善患者的生活品质。 CRD 未来的潜在治疗方法可能包括基因治疗、干细胞治疗和视网膜移植。展望未来，由于政府宣传计划的不断加强、临床试验的增加、基因治疗和视网膜植入的进步以及对个性化医疗的日益关注，锥桿细胞营养不良症市场预计将在 2025 年至 2030 年间大幅扩张。预计 2025-2030 年预测期内市场复合年增长率为 5.33%。

本报告对全球锥桿细胞营养不良症市场进行了深入分析，并提供了有关市场动态、COVID-19 的影响和竞争格局的资讯。

目录

第一章执行摘要

第 2 章 简介

• 视锥细胞-视桿细胞营养不良：概述
  • 视锥细胞-视桿细胞营养不良症简介
• 视锥细胞-视桿细胞营养不良症的分类：概述
  • 视锥细胞-视桿细胞营养不良症的分类

第三章 全球市场分析

• 全球视锥细胞-视桿细胞营养不良症市场分析
  • 全球视锥细胞营养不良症市场概况
  • 视锥细胞营养不良症的全球市场规模
  • 全球视锥细胞-视桿细胞营养不良症市场按类型划分（X 连锁视锥细胞-视桿细胞营养不良症、体染色体显性视锥细胞-视桿细胞营养不良症、常染色体隐性视锥细胞-视桿细胞营养不良症）
  • 全球视锥细胞-视桿细胞营养不良症市场依治疗类型划分（基因治疗、干细胞治疗、视网膜植入手术等）
  • 全球视锥细胞-视桿细胞营养不良症市场（按最终用户划分）（医院、专科诊所、其他）
  • 全球视锥细胞营养不良症市场按地区划分（北美、欧洲、亚太地区、中东和非洲、拉丁美洲）
• 全球视锥细胞营养不良症市场：类型分析
  • 全球视锥细胞-视桿细胞营养不良症市场概况（按类型）
  • X 连锁视锥桿营养不良症的全球市场规模
  • 常染色体显性视锥细胞-视桿细胞营养不良症的全球市场规模
  • 常染色体隐性视锥桿营养不良症的全球市场规模
• 全球视锥细胞营养不良症市场：治疗类型分析
  • 全球视锥细胞-视桿细胞营养不良症市场概况（依治疗类型）
  • 视锥细胞营养不良症基因治疗的全球市场规模
  • 视锥细胞营养不良症干细胞治疗的全球市场规模
  • 视锥细胞营养不良症视网膜植入手术的全球市场规模
  • 其他视锥细胞营养不良症的全球市场规模
• 全球视锥细胞营养不良症市场：最终用户分析
  • 全球视锥细胞营养不良症市场：最终用户概览
  • 医院视锥桿营养不良症的全球市场规模
  • 专门诊所治疗视锥桿营养不良症的全球市场规模
  • 其他视锥细胞营养不良症的全球市场规模

第四章 区域市场分析

• 北美视锥细胞营养不良症市场：分析
  • 北美视锥细胞-视桿细胞营养不良症市场概况
  • 北美视锥细胞营养不良症市场规模
  • 北美视锥细胞营养不良症市场按地区划分（美国、加拿大、墨西哥）
  • 美国视锥细胞营养不良症市场规模
  • 加拿大视锥细胞营养不良症市场规模
  • 墨西哥视锥细胞营养不良症市场规模
• 欧洲视锥细胞-视桿细胞营养不良症市场：分析
  • 欧洲视锥细胞-视桿细胞营养不良症市场概况
  • 欧洲视锥细胞营养不良症市场规模
  • 欧洲视锥细胞营养不良症市场按地区划分（德国、英国、法国、义大利、欧洲其他地区）
  • 德国视锥桿营养不良症的市场规模
  • 英国视锥细胞营养不良症市场规模
  • 法国视锥细胞营养不良症的市场规模
  • 义大利视锥细胞营养不良症的市场规模
  • 其他欧洲视锥细胞营养不良症市场规模
• 亚太地区视锥细胞-视桿细胞营养不良症市场分析
  • 亚太地区视锥细胞-视桿细胞营养不良症市场概况
  • 亚太地区视锥细胞营养不良症市场规模
  • 亚太地区视锥细胞营养不良症市场（按地区划分）（中国、印度、日本、韩国、亚太其他地区）
  • 中国视锥桿营养不良症市场规模
  • 日本视锥细胞营养不良症市场规模
  • 印度视锥细胞营养不良症市场规模
  • 韩国视锥细胞营养不良症市场规模
  • 其他亚太地区视锥细胞营养不良症市场规模
• 中东和非洲视锥细胞营养不良症市场分析
  • 中东和非洲视锥细胞营养不良症市场概况
  • 中东和非洲视锥细胞营养不良症市场规模
• 拉丁美洲视锥细胞-视桿细胞营养不良症市场分析
  • 拉丁美洲视锥细胞-视桿细胞营养不良症市场概况
  • 拉丁美洲视锥细胞-视桿细胞营养不良症市场规模

第五章 新冠肺炎疫情的影响

• COVID-19 对全球视锥细胞营养不良症市场的影响
• COVID-19 对全球视锥细胞-视桿细胞营养不良症市场的影响

第六章 市场动态

• 成长动力
  • 视锥细胞-视桿细胞营养不良症盛行率不断上升
  • 增加研发活动
  • 罕见遗传疾病发生率不断上升
  • 提高对视锥细胞-视桿细胞营养不良症的认识
  • 医疗费用上涨
  • 视锥细胞-视桿细胞营养不良症的基因治疗
• 任务
  • 患者数量有限
  • 监管和安全问题
• 市场趋势
  • 临床试验激增
  • 开发新治疗方法
  • 新科技有助于早期发现

第七章 竞争格局

• 全球视锥细胞营养不良症市场：最新发展
• 全球视锥细胞营养不良症市场公司：现状

第八章 公司简介

• SparingVision
• Beacon Therapeutics
• Nanoscope Therapeutics, Inc.
• MeiraGTx Limited
• Ascidian Therapeutics, Inc.
• jCyte, Inc.
• BlueRock Therapeutics LP
• Zhongmou Therapeutics

Cone rod dystrophy is a term used to describe a group of genetic or inherited eye disorders that affect the cone cells of the retina. These cells line the back of the eye in the region known as the retina. Cone photoreceptor cells are present throughout the retina, but are concentrated in the central region (the macula). They are useful for central (reading) vision. Rod photoreceptor cells are present throughout the retina except for the very centre and they help with night vision. The global cone rod dystrophy market value stood at US$131.29 million in 2024, and is expected to reach US$177.59 million by 2030.

The global cone rod dystrophy market growth is driven by factors such as the rising awareness of genetic disorders and growing demand for effective treatments. Diabetes also have a major impact on the growth of the Cone rod dystrophy Market. As of recent estimates from the National Eye Institute, about 1 in 40,000 individuals are affected by cone-rod dystrophy in the US alone, highlighting the critical need for effective treatment options. Currently, there is no treatment to stop a person with Cone Rod Dystrophy (CRD) from losing their vision. The primary goal of treating CRD is to slow disease progression, preserve remaining vision, and improve the quality of life for affected individuals. Possible future treatments for CRD may include gene therapy, stem cell therapy, and retinal implants. Looking ahead, the cone rod dystrophy market is projected to expand significantly from 2025 to 2030, fueled by rise in the government awareness programs, growing number of clinical trials, advancements in gene therapy and retinal implants, and increasing focus on personalized medicine. The market is expected to grow at a CAGR of 5.33% over the projected period of 2025-2030.

Market Segmentation Analysis:

By Type: The report provides the bifurcation of the global cone rod dystrophy market into three segments on the basis of type, namely, X-Linked Cone Rod Dystrophy, Autosomal Dominant Cone Rod Dystrophy, and Autosomal Recessive Cone Rod Dystrophy. The X-Linked Cone Rod Dystrophy segment dominated the X-Linked Cone Rod Dystrophy market in 2024, owing to the ongoing research which is exploring various potential therapeutic avenues, including gene therapies, pharmacological interventions targeting specific biochemical pathways involved in CRD pathogenesis, and neuroprotective agents aimed at preserving retinal function.

By Treatment Type: The report provides the bifurcation of the global cone rod dystrophy market into four segments on the basis of treatment type: Gene Therapy, Stem Cell Therapy, Retinal Implant Surgery, and Others. Gene therapy segment held the highest share in the market and and is expected to be the fastest-growing segment in the forecasted period. Currently there is no cure for Cone Rod Dystrophy, ongoing research into gene therapies holds promise for improving outcomes and potentially halting or slowing disease progression in the future. It refers to the transfer of functional genetic material into the affected cells to correct or replace the faulty genes, thereby potentially reversing the disease's progression, is expected to drive the cone rod dystrophy market during the forecast period. For instance, trials focused on adeno-associated virus (AAV) vectors show promise in delivering corrective genes to retinal cells. Several clinical trials are underway to evaluate the safety and efficacy of gene therapy for CRD.

By End User: The global cone rod dystrophy market can be divided into three segments, on the basis of end user, namely, drug Hospitals, Specialty Clinics, and Others. Hospitals segment held the highest share in the market, due to their comprehensive patient care services and advanced treatment options. The expansion of hospital infrastructure, particularly in emerging markets are driving growth. Future trends in hospitals involve the integration of advanced technologies, such as artificial intelligence and precision medicine, to enhance the delivery of several therapies for the treatment of CRD. The trend toward personalized medicine is expected to drive the growth. Moreover, the increasing collaboration between hospitals and biotechnology companies to conduct clinical trials and develop new therapies is likely to accelerate innovation and the adoption of several therapies to treat CRD in clinical practice.

By Region: The report provides insight into the global cone rod dystrophy market based on regions namely, North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. North America is the largest region of global cone rod dystrophy market, owing to rising cases of eye disorders. Also, increasing number of ophthalmic clinics has also led to market growth. The growing awareness and acceptance of early detection among patients and healthcare providers have also contributed to market expansion. Moreover, technological advancements in gene therapy and stem cell research, have opened new avenues for therapy development. Additionally, increased funding from both public and private sectors for research and clinical trials further supports the market's growth. The U.S. Food and Drug Administration (FDA) plays a crucial role in regulating and approving therapies, ensuring their safety and efficacy.

Asia Pacific is the fastest growing region of global cone rod dystrophy market, driven by a combination of increasing healthcare needs, significant investments in biotechnology, and supportive government policies. As a diverse and populous region, Asia Pacific offers immense potential for growth in therapies, particularly as countries within the region continue to advance their healthcare infrastructures and research capabilities. China is the largest region of Asia Pacific cone rod dystrophy market owing to significant investments in healthcare infrastructure and research. Japan is also a key player, with a significant market share. India is another significant market, with growing investments in healthcare and research contributing to the overall growth of the Cone Rod Dystrophy market in the region.

Market Dynamics:

Growth Drivers: The global cone rod dystrophy market has been rapidly growing over the past few years, due to factors such as increasing prevalence of cone rod dystrophy, rise in research and development activities, growing incidence of rare genetic disorders, rising awareness about cone rod dystrophy, rising healthcare expenditure, gene therapy for cone rod dystrophy, and many other factors. In the last few years, there has been a significant rise in instances of cone rod dystrophy, a condition that impacts about 2 million people globally. This ailment is a leading factor in causing vision loss among adults of working age. The rise in cone rod dystrophy cases globally is mainly due to two reasons: more people getting older and an increase in genetic disorders. The increasing prevalence of cone rod dystrophy is leading to a growing demand for the development of tailored therapies and interventions to address this condition.

Challenges: However, the global cone rod dystrophy market growth would be negatively impacted by various challenges such as, limited patient pool, and regulatory and safety considerations. The limited patient pool poses a significant challenge to the antiplatelet market. The rarity of the condition results in a limited patient pool, making it challenging for pharmaceutical companies to justify the high costs associated with research and development. Insurance coverage for these innovative treatments remains inconsistent, with many patients facing out-of-pocket expenses that can be prohibitive. This financial barrier can lead to disparities in access to care, particularly among low-income populations.

Trends: The global cone rod dystrophy market is projected to grow at a fast pace during the forecasted period, due to surge in clinical trials, development of novel therapies, newer techniques help in early detection, etc. The recent surge in clinical trials focusing on gene therapy for inherited retinal diseases underscores a pivotal shift towards more targeted therapies. The FDA has also reported a notable increase in the number of approved treatments for rare ocular disorders in the last decade, reflecting the growing commitment to addressing these unmet medical needs. Furthermore, the adoption of technologies like gene therapy has opened new avenues for treatment, potentially revolutionizing the management of cone-rod dystrophy. Moreover, collaboration between academic institutions, biotechnology firms, and patient advocacy groups can foster innovation and accelerate the development of new therapies. Partnerships aimed at raising awareness about the condition can also enhance patient recruitment for clinical trials, ultimately benefiting both patients and developers.

Impact Analysis of COVID-19 and Way Forward:

The COVID-19 pandemic initially disrupted the global cone rod dystrophy market by delaying clinical trials and research activities, but it also highlighted the potential of gene and stem cell therapies to develop treatment for cone rod dystrophy, leading to renewed interest and investment in the field. Post-COVID, the market is poised for significant growth as accelerated regulatory approvals and advancements in genetic and stem cell research are driving innovation and commercialization of new therapies.

Competitive Landscape:

The global cone rod dystrophy market is quite concentrated as the market is characterized by the presence of numerous players, including biotechnology companies, pharmaceutical companies, research institutes, hospitals, and specialty clinics, all of which are involved in various aspects of the market such as research, development, production, and commercialization of gene and stem cell therapies to treat cone rod dystrophy. Mergers and acquisitions are common as companies look to enhance their market position. Roche and Novartis continue to spearhead research initiatives aimed at advancing gene therapy and enhancing patient outcomes. The key players of the market are:

SparingVision

Beacon Therapeutics

Nanoscope Therapeutics, Inc.

MeiraGTx Limited

Ascidian Therapeutics, Inc.

jCyte, Inc.

BlueRock Therapeutics LP.

Zhongmou Therapeutics

The ongoing clinical trials of novel advanced therapies with improved efficiency and cost-effectiveness is positively contributing to market expansion, and entry of new advanced drugs into the market. Some recent approvals are as follows:

SparingVision's product, SPVN06, is gene agnostic treatment and therefore potentially capable of addressing more than 80 known genetic mutations of Retinitis Pigmentosa (RP). SPVN06 expresses proprietary neurotrophic factor (Rod derived Cone Viability Factor, RdCVF) and one enzyme reducing oxidative stress (Rod derived Cone Viability Factor Long form, RdCVFL) and is delivered via a single subretinal injection. The Company intends to start its first-in-human trial shortly after receiving a Clinical Trial Authorisation (CTA) and Investigational New Drug (IND). The first clinical trial will be a Phase I/II study aimed at testing the safety, tolerability, preliminary efficacy and quality of life of SPVN06.

Table of Contents

1. Executive Summary

2. Introduction

• 2.1 Cone Rod Dystrophy: An Overview
  • 2.1.1 Introduction to Cone Rod Dystrophy
• 2.2 Cone Rod Dystrophy Segmentation: An Overview
  • 2.2.1 Cone Rod Dystrophy Segmentation

3. Global Market Analysis

• 3.1 Global Cone Rod Dystrophy Market: An Analysis
  • 3.1.1 Global Cone Rod Dystrophy Market: An Overview
  • 3.1.2 Global Cone Rod Dystrophy Market by Value
  • 3.1.3 Global Cone Rod Dystrophy Market by Type (X-Linked Cone Rod Dystrophy, Autosomal Dominant Cone Rod Dystrophy, and Autosomal Recessive Cone Rod Dystrophy)
  • 3.1.4 Global Cone Rod Dystrophy Market by Treatment Type (Gene Therapy, Stem Cell Therapy, Retinal Implant Surgery, and Others)
  • 3.1.4 Global Cone Rod Dystrophy Market by End User (Hospitals, Specialty Clinics, and Others)
  • 3.1.5 Global Cone Rod Dystrophy Market by Region (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America)
• 3.2 Global Cone Rod Dystrophy Market: Type Analysis
  • 3.2.1 Global Cone Rod Dystrophy Market by Type: An Overview
  • 3.2.2 Global X-Linked Cone Rod Dystrophy Market by Value
  • 3.2.3 Global Autosomal Dominant Cone Rod Dystrophy Market by Value
  • 3.2.4 Global Autosomal Recessive Cone Rod Dystrophy Market by Value
• 3.3 Global Cone Rod Dystrophy Market: Power Source Analysis
  • 3.3.1 Global Cone Rod Dystrophy Market by Treatment Type: An Overview
  • 3.3.2 Global Gene Therapy Cone Rod Dystrophy Market by Value
  • 3.3.3 Global Stem Cell Therapy Cone Rod Dystrophy Market by Value
  • 3.3.4 Global Retinal Implant Surgery Cone Rod Dystrophy Market by Value
  • 3.3.5 Global Others Cone Rod Dystrophy Market by Value
• 3.4 Global Cone Rod Dystrophy Market: End User Analysis
  • 3.4.1 Global Cone Rod Dystrophy Market by End User: An Overview
  • 3.4.2 Global Hospitals Cone Rod Dystrophy Market by Value
  • 3.4.3 Global Specialty Clinics Cone Rod Dystrophy Market by Value
  • 3.4.4 Global Others Cone Rod Dystrophy Market by Value

4. Regional Market Analysis

• 4.1 North America Cone Rod Dystrophy Market: An Analysis
  • 4.1.1 North America Cone Rod Dystrophy Market: An Overview
  • 4.1.2 North America Cone Rod Dystrophy Market by Value
  • 4.1.3 North America Cone Rod Dystrophy Market by Region (The US, Canada and Mexico)
  • 4.1.4 The US Cone Rod Dystrophy Market by Value
  • 4.1.5 Canada Cone Rod Dystrophy Market by Value
  • 4.1.6 Mexico Cone Rod Dystrophy Market by Value
• 4.2 Europe Cone Rod Dystrophy Market: An Analysis
  • 4.2.1 Europe Cone Rod Dystrophy Market: An Overview
  • 4.2.2 Europe Cone Rod Dystrophy Market by Value
  • 4.2.3 Europe Cone Rod Dystrophy Market by Region (Germany, UK, France, Italy, and Rest of Europe)
  • 4.2.4 Germany Cone Rod Dystrophy Market by Value
  • 4.2.5 UK Cone Rod Dystrophy Market by Value
  • 4.2.6 France Cone Rod Dystrophy Market by Value
  • 4.2.7 Italy Cone Rod Dystrophy Market by Value
  • 4.2.8 Rest of Europe Cone Rod Dystrophy Market by Value
• 4.3 Asia Pacific Cone Rod Dystrophy Market: An Analysis
  • 4.3.1 Asia Pacific Cone Rod Dystrophy Market: An Overview
  • 4.3.2 Asia Pacific Cone Rod Dystrophy Market by Value
  • 4.3.3 Asia Pacific Cone Rod Dystrophy Market by Region (China, India, Japan, South Korea, and Rest of Asia Pacific)
  • 4.3.4 China Cone Rod Dystrophy Market by Value
  • 4.3.5 Japan Cone Rod Dystrophy Market by Value
  • 4.3.6 India Cone Rod Dystrophy Market by Value
  • 4.3.7 South Korea Cone Rod Dystrophy Market by Value
  • 4.3.8 Rest of Asia Pacific Cone Rod Dystrophy Market by Value
• 4.4 Middle East & Africa Cone Rod Dystrophy Market: An Analysis
  • 4.4.1 Middle East & Africa Cone Rod Dystrophy Market: An Overview
  • 4.4.2 Middle East & Africa Cone Rod Dystrophy Market by Value
• 4.5 Latin America Cone Rod Dystrophy Market: An Analysis
  • 4.5.1 Latin America Cone Rod Dystrophy Market: An Overview
  • 4.5.2 Latin America Cone Rod Dystrophy Market by Value

5. Impact of COVID-19

• 5.1 Impact of COVID-19 on Global Cone Rod Dystrophy Market
• 5.2 Post COVID-19 Impact on Global Cone Rod Dystrophy Market

6. Market Dynamics

• 6.1 Growth Drivers
  • 6.1.1 Increasing Prevalence of Cone Rod Dystrophy
  • 6.1.2 Rise in Research and Development Activities
  • 6.1.3 Growing Incidence of Rare Genetic Disorders
  • 6.1.4 Rising Awareness about Cone Rod Dystrophy
  • 6.1.5 Rising Healthcare Expenditure
  • 6.1.6 Gene Therapy for Cone Rod Dystrophy
• 6.2 Challenges
  • 6.2.1 Limited Patient Pool
  • 6.2.2 Regulatory and Safety Considerations
• 6.3 Market Trends
  • 6.3.1 Surge in Clinical Trials
  • 6.3.2 Development of Novel Therapies
  • 6.3.3 Newer Techniques Help in Early Detection

7. Competitive Landscape

• 7.1 Global Cone Rod Dystrophy Market: Recent Developments
• 7.2 Global Cone Rod Dystrophy Market Players: Current Landscape

8. Company Profiles

• 8.1 SparingVision
  • 8.1.1 Business Overview
  • 8.1.2 Business Strategies
• 8.2 Beacon Therapeutics
  • 8.2.1 Business Overview
  • 8.2.2 Business Strategies
• 8.3 Nanoscope Therapeutics, Inc.
  • 8.3.1 Business Overview
  • 8.3.2 Business Strategies
• 8.4 MeiraGTx Limited
  • 8.4.1 Business Overview
  • 8.4.2 Business Strategies
• 8.5 Ascidian Therapeutics, Inc.
  • 8.5.1 Business Overview
  • 8.5.2 Business Strategies
• 8.6 jCyte, Inc.
  • 8.6.1 Business Overview
  • 8.6.2 Business Strategies
• 8.7 BlueRock Therapeutics LP
  • 8.7.1 Business Overview
  • 8.7.2 Business Strategies
• 8.8 Zhongmou Therapeutics
  • 8.8.1 Business Overview
  • 8.8.2 Business Strategy

List of Figures

• Figure 1: Cone Rod Dystrophy Segmentation
• Figure 2: Global Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
• Figure 3: Global Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
• Figure 4: Global Cone Rod Dystrophy Market by Type; 2024 (Percentage, %)
• Figure 5: Global Cone Rod Dystrophy Market by Treatment Type; 2024 (Percentage, %)
• Figure 6: Global Cone Rod Dystrophy Market by End user; 2024 (Percentage, %)
• Figure 7: Global Cone Rod Dystrophy Market by Region; 2024 (Percentage, %)
• Figure 8: Global X-Linked Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
• Figure 9: Global X-Linked Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
• Figure 10: Global Autosomal Dominant Cone Rod Dystrophy Market by Type; 2023-2024 (US$ Million)
• Figure 11: Global Autosomal Dominant Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
• Figure 12: Global Autosomal Recessive Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
• Figure 13: Global Autosomal Recessive Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
• Figure 14: Global Gene Therapy Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
• Figure 15: Global Gene Therapy Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
• Figure 16: Global Stem Cell Therapy Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
• Figure 17: Global Stem Cell Therapy Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
• Figure 18: Global Retinal Implant Surgery Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
• Figure 19: Global Retinal Implant Surgery Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
• Figure 20: Global Others Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
• Figure 21: Global Others Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
• Figure 22: Global Hospitals Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
• Figure 23: Global Hospitals Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
• Figure 24: Global Specialty Clinics Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
• Figure 25: Global Specialty Clinics Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
• Figure 26: Global Others Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
• Figure 27: Global Others Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
• Figure 28: North America Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
• Figure 29: North America Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
• Figure 30: North America Cone Rod Dystrophy Market by Region; 2024 (Percentage, %)
• Figure 31: The US Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
• Figure 32: The US Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
• Figure 33: Canada Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
• Figure 34: Canada Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
• Figure 35: Mexico Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
• Figure 36: Mexico Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
• Figure 37: Europe Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
• Figure 38: Europe Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
• Figure 39: Europe Cone Rod Dystrophy Market by Region; 2024 (Percentage, %)
• Figure 40: Germany Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
• Figure 41: Germany Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
• Figure 42: UK Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
• Figure 43: UK Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
• Figure 44: France Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
• Figure 45: France Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
• Figure 46: Italy Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
• Figure 47: Italy Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
• Figure 48: Rest of Europe Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
• Figure 49: Rest of Europe Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
• Figure 50: Asia Pacific Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
• Figure 51: Asia Pacific Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
• Figure 52: Asia Pacific Cone Rod Dystrophy Market by Region; 2024 (Percentage, %)
• Figure 53: China Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
• Figure 54: China Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
• Figure 55: Japan Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
• Figure 56: Japan Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
• Figure 57: India Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
• Figure 58: India Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
• Figure 59: South Korea Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
• Figure 60: South Korea Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
• Figure 61: Rest of Asia Pacific Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
• Figure 62: Rest of Asia Pacific Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
• Figure 63: Middle East & Africa Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
• Figure 64: Middle East & Africa Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
• Figure 65: Latin America Cone Rod Dystrophy Market by Value; 2023-2024 (US$ Million)
• Figure 66: Latin America Cone Rod Dystrophy Market by Value; 2025-2030 (US$ Million)
• Figure 67: Rising Healthcare Expenditure